

ABSTRACT

The present invention relates to the treatment or prevention of neurodegenerative polyglutamine diseases by the administration of effective amounts of L-methionine S-sulfoximine, L-ethionine S-sulfoximine, glufosinate and/or branched chain α -keto acids. In particular, the present invention relates to the treatment or prevention of Huntington's disease and other polyglutamine disorders caused by expanded genomic CAG nucleotides.